ClinicalTrials.gg
Active, not recruitingNCT04185883Updated Oct 22, 2025

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

A Phase 1 interventional study of Sotorasib and Trametinib in Advanced Solid Tumors and Kirsten Rat Sarcoma (KRAS) pG12C Mutation, sponsored by Amgen. Active, not recruiting at 90 sites in 13 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
610
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
  • Kirsten Rat Sarcoma (KRAS) pG12C Mutation
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women greater than or equal to 18 years old.
  • documented, locally-advanced or with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements. In the United States, this test must be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.

Exclusion criteria

Exclusion Criteria:

  • Primary brain tumor.
  • Spinal cord compression, or untreated, or symptomatic, or active , or from non-brain tumors.
  • Myocardial infarction within 6 months of study day 1.
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
610 participants (actual)

Study arms

  • Experimental
    Sotorasib + trametinib + panitumumab

    Experimental: Sotorasib + trametinib + panitumumab Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.

    Drug: Sotorasib · Drug: Trametinib · Drug: Panitumumab

  • Experimental
    Sotorasib + RMC-4630

    Experimental: Sotorasib + RMC-4630 Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors.

    Drug: Sotorasib · Drug: RMC-4630

  • Experimental
    Sotorasib + afatinib

    Experimental: Sotorasib + afatinib Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.

    Drug: Sotorasib · Drug: Afatinib

  • Experimental
    Sotorasib + panitumumab +/- chemotherapy

    Experimental: Sotorasib + panitumumab +/- chemotherapy Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.

    Drug: Sotorasib · Drug: Panitumumab · Drug: IV Chemotherapy (Regimen 1)

  • Experimental
    Sotorasib + atezolizumab

    Experimental: Sotorasib + atezolizumab Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.

    Drug: Sotorasib · Drug: Atezolizumab

  • Experimental
    Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab

    Experimental: Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.

    Drug: Sotorasib · Drug: Pembrolizumab · Drug: Carboplatin, pemetrexed, docetaxel, paclitaxel

  • Experimental
    Sotorasib Monotherapy

    Experimental: Sotorasib only Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases.

    Drug: Sotorasib

  • Experimental
    Sotorasib + palbociclib

    Experimental: Sotorasib + palbociclib Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.

    Drug: Sotorasib · Drug: Palbociclib

  • Experimental
    Sotorasib + pembrolizumab

    Experimental: Sotorasib + pembrolizumab Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant non small cell lung cancer. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant non small cell lung cancer.

    Drug: Sotorasib · Drug: Pembrolizumab

  • Experimental
    Sotorasib + MVASI® (bevacizumab-awwb)+ Chemotherapy

    Experimental: Sotorasib + MVASI® (bevacizumab-awwb)+ chemotherapy Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced colorectal cancer.

    Drug: Sotorasib · Drug: MVASI® (bevacizumab-awwb) · Drug: IV Chemotherapy (Regimen 1) · Drug: IV Chemotherapy (Regimen 2)

  • Experimental
    Sotorasib + TNO155

    Experimental: Sotorasib + TNO155 Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. * Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.

    Drug: Sotorasib · Drug: TNO155

  • Experimental
    Sotorasib + BI 1701963

    Experimental: Sotorasib + BI 1701963 Dose Exploration and Dose Expansion * Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. * Upon completion of dose exploration part of the study the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer and advanced colorectal cancer.

    Drug: Sotorasib · Drug: BI 1701963

  • Experimental
    Sotorasib + AMG 404

    Experimental: Sotorasib + AMG 404 Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors

    Drug: Sotorasib · Drug: AMG 404

  • Experimental
    Sotorasib + everolimus

    Experimental: Sotorasib + everolimus Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.

    Drug: Sotorasib · Drug: Everolimus

Interventions

  • Sotorasib administered orally as a tablet.

  • Trametinib administered orally as a tablet.

  • RMC-4630 administered orally as a capsule.

  • afatinib administered orally as a tablet.

  • pembrolizumab administered as an intravenous (IV) infusion.

  • Panitumumab administered as an IV infusion.

  • DrugCarboplatin, pemetrexed, docetaxel, paclitaxel

    Drug pages: Carboplatin · Pemetrexed · Docetaxel · Paclitaxel

    Carboplatin, pemetrexed, docetaxel administered as an IV infusion.

  • Atezolizumab administered as an IV injection.

  • Palbociclib administered orally as a tablet.

  • DrugMVASI® (bevacizumab-awwb)

    MVASI® (bevacizumab-awwb) administered as an IV infusion.

  • DrugTNO155

    TNO155 administered orally as a capsule.

  • DrugIV Chemotherapy (Regimen 1)

    Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.

  • DrugIV Chemotherapy (Regimen 2)

    IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.

  • BI 1701963 administered orally

  • AMG 404 administered as an IV infusion.

  • Everolimus administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: 12 Months

  2. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: 12 Months

  3. Number of Participants with Treatment-related Adverse Events

    Time frame: 12 Months

  4. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: 12 Months

  5. Number of Participants with Clinically Significant Changes in ECG Measurements

    Time frame: 12 Months

  6. Number of Participants with Clinically Significant Changes in Laboratory Test Values

    Time frame: 12 Months

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: 12 Months

  2. Time to Maximum Plasma Concentration (Tmax)

    Time frame: 12 Months

  3. Area Under the Plasma Concentration-time Curve (AUC)

    Time frame: 12 Months

  4. Objective Response Rate

    Time frame: 12 Months

  5. Disease Control Rate

    Time frame: 12 Months

  6. Duration of Response

    Time frame: 12 Months

  7. Progression-free Survival

    Time frame: 12 Months

  8. Duration of Stable Disease

    Time frame: 12 Months

  9. Time to Response

    Time frame: 12 Months

  10. Overall Survival

    Time frame: 12 Months

  11. Sotorasib + EGFR Inhibitor +/- Chemotherapeutic Regimen Only: Quantification of Plasma Levels

    Time frame: 12 Months

  12. Sotorasib Monotherapy Only: Intracranial Objective Response Rate

    Intracranial objective response rate assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM).

    Time frame: 12 Months

  13. Sotorasib Monotherapy Only: Intracranial Disease Control Rate

    Intracranial disease control rate assessed per RANO-BM.

    Time frame: 12 Months

  14. Sotorasib Monotherapy Only: Intracranial Duration of Response

    Intracranial duration of response assessed per RANO-BM.

    Time frame: 12 Months

  15. Sotorasib Monotherapy Only: Time to Intracranial Radiation Therapy

    Time frame: 12 Months

  16. Sotorasib Monotherapy Only: Intracranial Progression-free Survival (PFS)

    Intracranial PFS assessed per RANO-BM.

    Time frame: 12 Months

  17. Sotorasib Monotherapy Only: Non-intracranial Progression-free Survival (PFS)

    Non-intracranial PFS assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Time frame: 12 Months

  18. Sotorasib Monotherapy Only: Overall Progression-free Survival (PFS)

    Overall PFS assessed per RECIST 1.1 and RANO-BM.

    Time frame: 12 Months

  19. Sotorasib + TNO155 Only: Best Overall Response

    Time frame: 12 Months

  20. Sotorasib + Afatinib + Loperamide Only: Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: 12 Months

  21. Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: 12 Months

  22. Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-related Adverse Events

    Time frame: 12 Months

  23. Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: 12 Months

  24. Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in ECG Measurements

    Time frame: 12 Months

  25. Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Laboratory Test Values

    Time frame: 12 Months

07

Study locations

90 sites
08

References and documents

Publications

  • Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4. PubMed 38177853 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Dec 2026, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 4, 2019
StartActual
Dec 17, 2019
Primary completionEst.
Dec 17, 2026
CompletionEst.
Dec 5, 2027
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04185883
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Dec 17, 2019
Primary completion
Dec 17, 2026 (estimated)
Completion
Dec 5, 2027 (estimated)
Last update
Oct 22, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sotorasib · Vociprotafib · Batoprotafib · Pan-KRAS Inhibitor BI 1701963 · Zeluvalimab

Start the discussion